Lilly(US:LLY) GLP1减重宝典·2025-11-13 10:41Core Viewpoint - The article discusses the recent developments regarding the dual agonist Tirzepatide, highlighting its approval for new indications in China, which expands its market potential in the treatment of type 2 diabetes and obesity [2][4][8]. Group 1: Product Approval and Indications - Tirzepatide, developed by Eli Lilly, is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [3][5]. - The drug was approved in the U.S. in May 2022 for the treatment of type 2 diabetes and received its first approval in China in May 2024 for adult patients with inadequate blood sugar control on diet and exercise, along with metformin and/or sulfonylureas [4][5]. - In July 2024, Tirzepatide was approved in China for long-term weight management in adults with obesity (BMI ≥ 28 kg/m²) or overweight (BMI ≥ 24 kg/m² with at least one weight-related comorbidity) [4][5]. Group 2: Market Implications - The approval of Tirzepatide strengthens Eli Lilly's position in the metabolic disease treatment landscape in China, where there is a large population of patients with obesity and type 2 diabetes, providing significant market opportunities [8]. - As the first GIP/GLP-1 dual agonist, Tirzepatide offers treatment options in both blood sugar control and weight management, which is expected to have a substantial impact on the market [8]. - The expansion of Tirzepatide's indications is a key strategic move for Eli Lilly, particularly in the obesity and metabolic disease sectors, potentially solidifying its market position in diabetes treatment and increasing its relevance in weight management [8].